Pancreatic Adenocarcinoma Treatment Market size is anticipated to reach USD 10 billion by the end of 2035, growing at a CAGR of 14% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of pancreatic adenocarcinoma treatment was over USD 2 billion. The growth of the market can be attributed to the rising prevalence of pancreatic adenocarcinoma among people across the world. The changing lifestyle habits and adoption of alcohol are estimated to boost market growth across the world. The increasing prevalence of obesity is also estimated to drive market growth around the world. As of 2022 reports, more than 1 billion population across the globe are suffering from obesity with over 600 million adults, 40 million children, and more than 300 million adolescents. The increasing number of financially funded research projects by the National Cancer Institute to develop medications and treatments is estimated to propel market growth. Some of the other projects that are funded include the Pancreatic Cancer Cohort Consortium (PCDC), Pancreatic Cancer Microenvironment Network (PaCMEN), Pancreatic Ductal Adenocarcinoma (PDAC), Stromal Reprogramming Consortium (PSC), RAS Initiative, and Pancreatic Specialized Programs of Research Excellence (Pancreatic SPOREs).
Poor diet and unhealthy lifestyle practices are fueling the market growth in the coming years. The market growth is also attributed to the rising incidence of diabetic patients across the world as well as the high consumption of sugar and sweet foods. The number of people suffering from diabetes across the world included over 400 million in 2020 and is projected to increase by over half a billion by 2040. Increasing demand for packed foods and beverages across the globe is also estimated to propel market growth in the coming years. The lack of therapeutic procedures and early diagnostic tests for pancreatic adenocarcinoma is estimated to propel the growth of the market during the forecast period.
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
~14% |
|
Base Year Market Size (2022) |
~ USD 2 Billion |
|
Forecast Year Market Size (2035) |
~ USD 10 Billion |
|
Regional Scope |
|
Growth Drivers
Challenges
The side effects of chemotherapy include pain, dizziness, fever, vomiting, and frequent bowel movement and the side effects of radiation therapy include diarrhea, shortness of breath, change in taste, and urinary and bladder problems. All these factors are estimated to be the reason for the hampering of market growth.
Type (Chemotherapy, Targeted Therapy)
The global pancreatic adenocarcinoma treatment market is segmented and analyzed for demand and supply by type into chemotherapy, targeted therapy, and others. Out of these types, the chemotherapy segment is estimated to gain the largest market share of about ~40% in the year 2035. The growth of the segment can be attributed to the increasing number of patients in the need of chemotherapy. Chemotherapy is the first line of treatment in cancer disorders along with medications. More than 26% of people across the UK are estimated to have chemotherapy as the primary treatment for pancreatic cancer as of 2020. The increasing use of chemotherapy and targeted therapy for cancer cell isolation in tumor formation is estimated to propel the market segment growth as per the market analysis. The increasing presence of competent practitioners and increasing medical facilities across the world are expected to drive market segment growth in the coming years. The growing number of hospitals and clinics that provide chemotherapy with advanced equipment and decent infrastructure is also estimated to fuel the market segment growth during the forecast period.
Affected Area (Exocrine, Endocrine)
The global pancreatic adenocarcinoma treatment market is also segmented and analyzed for demand and supply by affected areas into exocrine and endocrine. Amongst these two segments, the exocrine segment is expected to garner a significant share of around ~56% in the year 2035. The pancreas is mostly composed of exocrine cells compared to endocrine cells in the body is estimated to drive the market segment growth. The growth of the segment is attributed to the increasing prevalence of exocrine cancers. More than 90% of pancreatic cancers across the world are exocrine tumors as of estimations in 2022. Cancer in the ducts affects the exocrine cells of the pancreas causing exocrine cancer and is estimated to drive market growth across the world. High awareness and technological advancements in endocrine cancer diagnostics or tumor diagnosis among people are estimated to boost the market segment growth in the coming years. The increasing privatization across the world and an increasing number of hospitals with chemotherapy and radiology treatment are estimated to propel the market growth in the coming years.
Our in-depth analysis of the global market includes the following segments:
|
By Type |
|
|
By Affected Area |
|
North American Market Forecast
The market share of pancreatic adenocarcinoma treatment in North America, amongst the market in all the other regions, is projected to be the largest with a share of about ~33% by the end of 2035. The growth of the market can be attributed majorly to the increasing prevalence of pancreatic adenocarcinoma disease across the region. The increasing population across the region is estimated to propel the market growth along with the changing food habits. The growing cancer rate across the region with a high number of patients under treatment is estimated to fuel the growth of the market. Also, the increased number of key players in the region interested in investment in the healthcare sector is estimated to hike the market growth across the region. The presence of a large population suffering from the disease and increasing acceptance of pancreatic treatment procedures in the region. As per the National Cancer Institute, in 2021, 60,430 people in the United States were evaluated to suffer from pancreatic cancer. The total number of cases is predicted to rise by 3.2 percent since the previous year. In addition, the strong presence of major market players is also expected to expand the region’s market in the upcoming years. Moreover, the market in the North America is projected to witness noteworthy growth during the forecast period, which can be ascribed to the rising occurrence of pancreatic adenocarcinoma and the growing establishment of critical care centers in the region.
Europe Market Forecast
The European pancreatic adenocarcinoma treatment market is estimated to be the second largest, registering a share of about ~26% by the end of 2035. The growth of the market can be attributed majorly to the high consumption of alcohol and beverages across the region. Increasing research and development activities across the region for the invention in the discovery of new treatment procedures and drug therapies is estimated to hike the market growth. The market growth is also attributed to the increasing number of people who smoke cigarettes is estimated to suffer pancreatic cancer across the region. The growing number of people with obesity rates in the region is also estimated to increase the growth of the market during the forecast period. The gastrointestinal problems and digestive issues in people owing to the high consumption of cheese and other sugary products are estimated to fuel market growth. The presence of many key players across the region who are investing in the research and development of diagnostic tests is estimated to have a positive impact on the market growth. The presence of a very simple approval process for the new clinical trial drugs and treatment procedures in the region is also expected to hike the market growth.
APAC Market Statistics
Further, the market in the Asia Pacific, amongst the market in all the other regions, is projected to hold a majority of the share by the end of 2035. The well-established clinics in the region have contributed significantly to the market's growth. The number of people suffering from pancreatic adenocarcinoma disease is also estimated to propel the market in the coming years. The increasing number of diagnostic tests occurring in the region with a high prevalence rate is also driving the market growth. The growing healthcare expenditure across the region to prevent the incidence of cancer is estimated to propel the market growth. The rising pharmaceutical companies across the region with clinical trials to develop new drugs are estimated to hike the market growth. The rising number of clinical care centers and hospitals with facilities for targeted therapy, chemotherapy, and radiotherapy is estimated to propel the market growth. The increasing government initiatives to increase awareness among people regarding diagnostic awareness are driving market growth across the region.
Amgen Inc.’s new drug targeting KRAS mutations was approved by the U.S. Food and Drug Administration. This is the first-ever therapy developed to treat KRAS cancers, which are often altered in the colon, lung, and pancreatic areas.
Novartis AG declared that US Food and Drug Administration granted the NIS793 with Orphan Drug Designation (ODD) along with standard chemotherapy care for the treatment of pancreatic cancer.
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?